<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088513</url>
  </required_header>
  <id_info>
    <org_study_id>SAST</org_study_id>
    <secondary_id>2018001</secondary_id>
    <nct_id>NCT04088513</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)</brief_title>
  <acronym>SAST</acronym>
  <official_title>A Randomized, Double-blind, Active-Controlled Trial Comparing the Safety and Efficacy of Aspirin Versus Clopidogrel in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aspirin was reported to induce hemolysis in patients with glucose-6-phosphate dehydrogenase&#xD;
      (G6PD) deficiency on some occasions, while still widely uesd for stroke prevention. The SAST&#xD;
      trial is designed to evaluate the safety and efficacy of aspirin in patients this enzyme&#xD;
      disorder.The primary purpose of the trial is to evaluate the hemolytic effects of a 3-month&#xD;
      regimen of aspirin 100mg/d versus a 3-month regimen of clopidogrel 75mg/d.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This SAST trial is a prospective, multicenter, randomized, double-blind trial.440 acute&#xD;
      ischemic stroke (AIS) patients with G6PD deficiency will be randomized to receive a 3-month&#xD;
      regimen of aspirin 100mg/d or clopidogrel 75mg/d. The primary end point is the proportion of&#xD;
      protocol-defined hemolysis at 90 days. Protocol-defined hemolysis is defined as one or more&#xD;
      of the following conditions: a) Hemoglobin level declined ≥2.5 g/dL from baseline, meanwhile&#xD;
      ruling out bleeding events. b) Hemoglobin level declined ≥25% from baseline, meanwhile ruling&#xD;
      out bleeding events. c) Clinically relevant hemolytic events, could manifested as fatigue,&#xD;
      back pain, anemia, dark urine and jaundice. The study consists of five visits including the&#xD;
      day of randomization, day 4, day10±3days, day27±3days, day90±7days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of protocol-defined hemolysis.</measure>
    <time_frame>90±5 days.</time_frame>
    <description>Protocol-defined hemolysis is defined as one or more of the following conditions: a) Hemoglobin level declined ≥2.5 g/dL from baseline, meanwhile ruling out bleeding events. b) Hemoglobin level declined ≥25% from baseline, meanwhile ruling out bleeding events. c) Clinically relevant hemolytic events, could manifested as fatigue, back pain, anemia, dark urine and jaundice, adjudicated by the adjudication committee ultimately.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin.</measure>
    <time_frame>4 days,10±3 days,27±3 days and 90±5 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in reticulocyte.</measure>
    <time_frame>4 days,10±3 days,27±3 days and 90±5 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in unconjugated bilirubin and total bilirubin.</measure>
    <time_frame>4 days,10±3 days,27±3 days and 90±5 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lactic dehydrogenase.</measure>
    <time_frame>4 days,10±3 days,27±3 days and 90±5 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of major bleed (GUSTO deﬁnition).</measure>
    <time_frame>90±5 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality.</measure>
    <time_frame>90±5 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of new clinical vascular events, deﬁned as the composite of stroke, transient ischemic attack (TIA), myocardial infarction and vascular death.</measure>
    <time_frame>90±5 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of functional independence defined as modified Rankin Scale score 0-2.</measure>
    <time_frame>90±5 days.</time_frame>
    <description>Modified Rankin Scale score ranges from 0 to 6, and lower score means more functional independence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of functional independence defined as Barthel Index 95-100.</measure>
    <time_frame>90±5 days.</time_frame>
    <description>Barthel Index ranges from 0 to 100, and higher score means more functional independence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in National Institutes of Health Stroke Scale</measure>
    <time_frame>90±5 days.</time_frame>
    <description>National Institutes of Health Stroke Scale ranges from 0 to 42, and higher scores indicate more severe neurologic deficits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life, assessed by EuroQoL-5 Dimensions questionnaire</measure>
    <time_frame>90±5 days.</time_frame>
    <description>EuroQoL-5 Dimensions questionnaire contains utility index score and visual analogue scale. Utility index score ranges from 0 to 1, and visual analogue scale ranges from 0 to 100. Higher scores indicate more healthy quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>G6PD Deficiency</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drugs:Aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drugs:Clopidogrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>This group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days.</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>Acetylsalicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>This group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days.</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age≥40 years(no upper limit)&#xD;
&#xD;
          2. Acute ischemic stroke within 14 days of symptoms onset;&#xD;
&#xD;
          3. Glucose-6-phosphate dehydrogenase deficiency screened in G6PD enzyme activity&#xD;
&#xD;
          4. Had not received aspirin 7 days prior to randomization&#xD;
&#xD;
          5. Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of hemorrhage or other pathology, such as vascular malformation, tumor,&#xD;
             abscess or other non-ischemic brain disease, base on head CT or MRI&#xD;
&#xD;
          2. Concomitant infections at the time of randomization&#xD;
&#xD;
          3. mRS&gt;2 prior to the presenting stroke&#xD;
&#xD;
          4. Hemoglobin&lt;10 g/dL prior to randomization&#xD;
&#xD;
          5. Received intravenous thrombolytic therapy or neurointervention treatment before&#xD;
             randomization&#xD;
&#xD;
          6. Clear indication for anticoagulation (presumed cardioembolism, eg, atrial&#xD;
             fibrillation, prosthetic cardiac valves or suspected endocarditis)&#xD;
&#xD;
          7. Clear indication for dual antiplatelet therapy (eg, minor stroke in 24h (NIHSS ≤3) or&#xD;
             endovascular therapy for the indexed event)&#xD;
&#xD;
          8. Anticipated concomitant antiplatelets other than aspirin or clopidogrel (eg,&#xD;
             GPIIb/IIIa inhibitors, ticlopidine, prasugrel, dipyridamole, ozagrel, cilostazol,&#xD;
             ticagrelor) and other antithrombotic agents with antiplatelet effects, including&#xD;
             traditional/herbal medicine agents.&#xD;
&#xD;
          9. Anticipated concomitant therapy with long-term (&gt;7 days) NSAIDs affecting platelet&#xD;
             function&#xD;
&#xD;
         10. Contraindication to clopidogrel or aspirin (1)Known allergic reactions (2)Severe&#xD;
             hepatic or renal dysfunction (Severe hepatic dysfunction is defined as serum ALT or&#xD;
             AST &gt;2 times the upper limit of the normal group；Severe renal dysfunction is defined&#xD;
             as serum creatinine &gt; 1.5 times the upper limit of the normal group) (3)Severe cardiac&#xD;
             failure（NYHA class Ⅲ or Ⅳ) (4)Asthma (5)Any history of Hemostatic disorder or systemic&#xD;
             bleeding (6)Any history of thrombocytopenia or neutropenia (7)Any history of&#xD;
             drug-induced hematologic or hepatic insufficiency (8)Low white blood cell (&lt;2×10^9/L)&#xD;
             or platelet count (&lt;100×10^9/L)&#xD;
&#xD;
         11. Any history of thalassemia, autoimmune hemolytic disease, aplastic anemia or other&#xD;
             severe hematologic diseases&#xD;
&#xD;
         12. Anticipated concomitant therapy with other contraindicated drugs for G6PD deficiency&#xD;
&#xD;
         13. Severe dysphagia to unable swallow the drugs&#xD;
&#xD;
         14. Concomitant infections and need for antimicrobial therapy&#xD;
&#xD;
         15. Intracranial hemorrhage or gastrointestinal bleed within 3 months, or major surgery&#xD;
             within 30 days&#xD;
&#xD;
         16. Stomach tumor or any other malignant tumor&#xD;
&#xD;
         17. Planed surgery or interventional treatment that may affect the study procedure&#xD;
&#xD;
         18. Severe non-cardiovascular comorbidity with life expectancy &lt;3 m&#xD;
&#xD;
         19. Female who is pregnant or lactating&#xD;
&#xD;
         20. Currently receiving an investigational drug or device&#xD;
&#xD;
         21. Inability to understand and/or comply with study procedures due to psychosis,&#xD;
             cognition impairment or emotion disturbance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinsheng Zeng, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinsheng Zeng, MD,PhD</last_name>
    <phone>13322800657</phone>
    <email>zengjs@pub.guangzhou.gd.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangdong Pharmaceutical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jinan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510632</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jieyang Municipal People's Hospital</name>
      <address>
        <city>Jieyang</city>
        <state>Guangdong</state>
        <zip>522000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meizhou City People's Hospital</name>
      <address>
        <city>Meizhou</city>
        <state>Guangdong</state>
        <zip>514000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yue Bei People's Hospital</name>
      <address>
        <city>Shaoguan</city>
        <state>Guangdong</state>
        <zip>512026</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yunfu People's Hospital</name>
      <address>
        <city>Yunfu</city>
        <state>Guangdong</state>
        <zip>527300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Forth Affiliated Hospital of Guangxi Medical Hospital</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi</state>
        <zip>545005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Hainan Medical University</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ganzhou Municipal Hospital</name>
      <address>
        <city>Ganzhou</city>
        <state>Jiangxi</state>
        <zip>341000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Forth Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 8, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Jinsheng Zeng, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>G6PD Deficiency</keyword>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Hemolysis</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Anti-platelet therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Glucosephosphate Dehydrogenase Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

